Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review

MLA

Robert J. Mentz, et al. “Sodium-Glucose Cotransporter-2 Inhibition for Heart Failure with Preserved Ejection Fraction and Chronic Kidney Disease with or without Type 2 Diabetes Mellitus: A Narrative Review.” Cardiovascular Diabetology, vol. 22, no. 1, Nov. 2023, pp. 1–20. EBSCOhost, https://doi.org/10.1186/s12933-023-02023-y.

APA

Robert J. Mentz, Stephen A. Brunton, & Janani Rangaswami. (2023). Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review. Cardiovascular Diabetology, 22(1), 1–20. https://doi.org/10.1186/s12933-023-02023-y

Chicago

Robert J. Mentz, Stephen A. Brunton, and Janani Rangaswami. 2023. “Sodium-Glucose Cotransporter-2 Inhibition for Heart Failure with Preserved Ejection Fraction and Chronic Kidney Disease with or without Type 2 Diabetes Mellitus: A Narrative Review.” Cardiovascular Diabetology 22 (1): 1–20. doi:10.1186/s12933-023-02023-y.